产品
编 号：F108771
分子式：C24H40O4
分子量：392.57
分子式：C24H40O4
分子量：392.57
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
280
In-stock
1g
320
In-stock
5g
744
In-stock
结构图
CAS No: 128-13-2
产品详情
生物活性：
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
体内研究：
Ursodeoxycholic acid (50、150 和 450 mg/kg；口服；每日一次，持续 21 天) 导致 C57BL/6J 野生型小鼠体重减轻。 Ursodeoxycholic acid (1% w/w 或 416 mg/kg；口服；7 天) 减少小鼠和仓鼠的 ACE2 表达。 Ursodeoxycholic acid (416 mg/kg；口服；7 天) 减少仓鼠感染 SARS-CoV-2。Animal Model:5 week old C57BL/6J WT mice (male and female)
Dosage:50, 150, and 450 mg/kg dissolved in corn oil
Administration:Oral gavage; daily for 21 days
Result:Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.
Animal Model:FVB/N mice and Syrian Golden Hamsters
Dosage:1% w/w for mice, 416 mg/kg for hamsters
Administration:In chow or oral gavage, 7 days
Result:Reduced ACE2 expression.
Animal Model:Syrian Golden Hamsters, SARS-CoV-2 infection model
Dosage:416 mg/kg
Administration:Oral gavage, 7 days
Result:Prevented transmission of SARS-CoV-2 in n=6 out of 9 sentinel animals (33% infected vs. 67% uninfected).
体外研究：
Ursodeoxycholic acid (10 μM；24 小时) 降低初级气道和肠道类器官中的 ACE2 和 SHP 水平，并通过 FXR 介导的 ACE2 调节减少多种细胞类型中的 SARS-CoV-2 感染。
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
体内研究：
Ursodeoxycholic acid (50、150 和 450 mg/kg；口服；每日一次，持续 21 天) 导致 C57BL/6J 野生型小鼠体重减轻。 Ursodeoxycholic acid (1% w/w 或 416 mg/kg；口服；7 天) 减少小鼠和仓鼠的 ACE2 表达。 Ursodeoxycholic acid (416 mg/kg；口服；7 天) 减少仓鼠感染 SARS-CoV-2。Animal Model:5 week old C57BL/6J WT mice (male and female)
Dosage:50, 150, and 450 mg/kg dissolved in corn oil
Administration:Oral gavage; daily for 21 days
Result:Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.
Animal Model:FVB/N mice and Syrian Golden Hamsters
Dosage:1% w/w for mice, 416 mg/kg for hamsters
Administration:In chow or oral gavage, 7 days
Result:Reduced ACE2 expression.
Animal Model:Syrian Golden Hamsters, SARS-CoV-2 infection model
Dosage:416 mg/kg
Administration:Oral gavage, 7 days
Result:Prevented transmission of SARS-CoV-2 in n=6 out of 9 sentinel animals (33% infected vs. 67% uninfected).
体外研究：
Ursodeoxycholic acid (10 μM；24 小时) 降低初级气道和肠道类器官中的 ACE2 和 SHP 水平，并通过 FXR 介导的 ACE2 调节减少多种细胞类型中的 SARS-CoV-2 感染。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备